Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Swedish Orphan Biovitrum AB (OTC: BIOVF).

Full DD Report for BIOVF

You must become a subscriber to view this report.


Recent News from (OTC: BIOVF)

Invitation - Presentation of Sobi's Q1 2018 Results
STOCKHOLM , April 19, 2018 /PRNewswire/ -- On 26 April, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the first quarter 2018. Financial analysts and media are invited to participate in a telephone conference, which will include a present...
Source: PR Newswire
Date: April, 19 2018 04:30
Fredrik Wetterlundh Joins Sobi(TM) as Head of Human Resources
STOCKHOLM , April 3, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Fredrik Wetterlundh as Head of Human Resources. Fredrik will join Sobi on 9 April 2018 and be part of Sobi's Extended Leadership Team. Fredrik Wetterlundh joins Sobi from Pfizer...
Source: PR Newswire
Date: April, 03 2018 04:30
Henrik Stenqvist is Joining Sobi(TM) as New Chief Financial Officer
STOCKHOLM , Feb. 26, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Henrik Stenqvist will be appointed Chief Financial Officer (CFO) and will join Sobi in late spring. Henrik will be a member of Sobi's Executive Committee. Henrik Stenqvist ...
Source: PR Newswire
Date: February, 26 2018 02:30
European advisory group backs expanded use for Swedish Orphan's Kineret
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval for Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Kineret (anakinra) for patients at least eight months old and weighing at least 10 kg with Still's ...
Source: SeekingAlpha
Date: February, 23 2018 09:52
Invitation - Presentation of Sobi's Q4/FY 2017 Results
STOCKHOLM , Feb. 13, 2018 /PRNewswire/ -- On 22 February, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2017. Financial analysts and media are invited to participate in a telephone conference, which will ...
Source: PR Newswire
Date: February, 13 2018 03:34
FDA signs off on Swedish Orphan's IND for MPS IIIA candidate SOBI003
The FDA has accepted Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Investigational New Drug (IND) application for SOBI003, a chemically modified human recombinant sulfamidase, for the potential treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also know as Sanfilippo syndrome type A...
Source: SeekingAlpha
Date: January, 23 2018 06:59
Bioverativ's Eloctate demonstrates positive effect on joints in hemophilia A patients; shares up 1%
Bioverativ ( BIVV +0.7% ) and commercialization partner Swedish Orphan Biovitrum ( OTCPK:BIOVF ) announce positive long-term results from a 47-subject multiyear open-label extension study, ASPIRE, assessing the effect on joint health from prophylactic treatment of ELOCTATE [Antihemophili...
Source: SeekingAlpha
Date: October, 31 2017 11:50
The First Patient Enrolled in the ReITIrate Study Evaluating Immune Tolerance Induction With Elocta®
STOCKHOLM , Oct. 27, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) announces today that the first patient has been enrolled in the open-label, multicentre ReITIrate study (NCT03103542). The ReITIrate study is designed to investigate the immune tolerance inductio...
Source: PR Newswire
Date: October, 27 2017 01:38
Sobi: Alprolix® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
STOCKHOLM , Oct. 25, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Alprolix® (eftrenonacog alfa), for the treatment of haemophilia B.  Alpr...
Source: PR Newswire
Date: October, 25 2017 02:38
Norbert Oppitz Joins Sobi(TM) as New Senior Vice President, Specialty Care
STOCKHOLM , Oct. 6, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Norbert Oppitz has been appointed Senior Vice President for the newly established business area Specialty Care. Norbert Oppitz brings considerable management experience ...
Source: PR Newswire
Date: October, 06 2017 02:28

 


About Swedish Orphan Biovitrum AB (OTC: BIOVF)

Logo for Swedish Orphan Biovitrum AB (OTC: BIOVF)

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally.

 

Contact Information

 

 

Current Management

  • Geoffrey McDonough / CEO
  • Annika Muskantor / CFO
  • Asa Stenqvist / VP, Investor Rel., VP, Corp. Comm.

Current Share Structure

  • Market Cap: $5,410,622,640 - 05/11/2018
  • Issue and Outstanding: 265,226,600 - 12/22/2011

 



Daily Technical Chart for (OTC: BIOVF)

Daily Technical Chart for (OTC: BIOVF)


Stay tuned for daily updates and more on (OTC: BIOVF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BIOVF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIOVF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BIOVF and does not buy, sell, or trade any shares of BIOVF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/